Latest Market Expansion News

I Synergy Group Limited has announced a renounceable entitlement offer aiming to raise approximately $1 million to fund new projects and operational growth. The offer is fully underwritten and open to shareholders across multiple Asia-Pacific markets.

Adveritas Limited reports a record 61% increase in annualised recurring revenue, driven by strong gains in sports betting and new product launches, while preparing for a strategic expansion into North America.

Cardiex Limited has gained Therapeutic Goods Administration approval for its CONNEQT Pulse device, paving the way for commercial expansion in Australia alongside its established US presence.

HITIQ has secured a pivotal one-year deal with the South Metro Junior Football League, positioning its PROTEQT concussion management system at the heart of junior sports safety. This move complements existing partnerships and signals a strong push into Australia’s grassroots sports market.

Singular Health Group has completed a $773,000 placement with Marin and Sons, alongside exercising options and issuing shares under its employee incentive plan, strengthening its capital base.

Papyrus Australia has secured a pivotal contract with UniSA to establish a Rapid Prototyping and R&D facility, advancing its sustainable packaging technology and commercial production plans.

dorsaVi has secured a three-year agreement with SANO Health to deploy its ViSafe+ wearable sensor technology across remote mining sites, reinforcing its foothold in high-risk occupational health sectors.

Little Green Pharma Ltd has reported a robust turnaround for FY2025, posting a $3.3 million profit after tax on revenues up 43%, driven by strong growth in Australia and Europe and strategic acquisitions.

Pacific Edge Limited has launched a NZ$20 million capital raise to bolster its cash reserves amid the loss of Medicare coverage for its bladder cancer diagnostic tests, aiming to accelerate US market adoption and support new product development.

Regal Partners Limited reported a stellar 2024 with a 141% jump in average funds under management to $14.4 billion and a near tripling of net profit after tax. Strategic acquisitions and offshore expansion underpin its growth trajectory.

TruScreen Group Limited has announced a capital raising initiative involving Placement and Share Purchase Plan (SPP) Options, aiming to secure approximately NZ$3 million to fund strategic growth and working capital needs. The offer, subject to shareholder approval, includes up to 80.9 million Placement Options and 55.5 million SPP Options exercisable at A$0.02.

TruScreen Ordinary Shares Group Limited has announced a combined share purchase plan and placement to raise approximately NZD 1.78 million, aiming to accelerate its international expansion and cervical cancer screening initiatives.